1. FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes. Issue 9 (12th August 2020) Authors: Rosenberg, Matthew; Sheehan, Sarah; Zhou, Esther; Pinnow, Ellen; Burnell, Jessica; Romine, Morgan; Dal Pan, Gerald Journal: Pharmacoepidemiology and drug safety Issue: Volume 29:Issue 9(2020) Page Start: 1022 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Predictive Analysis of First Abbreviated New Drug Application Submission for New Chemical Entities Based on Machine Learning Methodology. Issue 1 (12th June 2019) Authors: Hu, Meng; Babiskin, Andrew; Wittayanukorn, Saranrat; Schick, Andreas; Rosenberg, Matthew; Gong, Xiajing; Kim, Myong‐Jin; Zhang, Lei; Lionberger, Robert; Zhao, Liang Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 1(2019) Page Start: 174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation. (June 2020) Authors: Wolff, Carolyn; Dowd, William N.; Ali, Mir M.; McClellan, Chandler; Meinhofer, Angelica; Glos, Lukas; Mutter, Ryan; Rosenberg, Matthew; Schick, Andreas Journal: Addictive behaviors Issue: Volume 105(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Trends and economic drivers for United States naloxone pricing, January 2006 to February 2017. (November 2018) Authors: Rosenberg, Matthew; Chai, Grace; Mehta, Shekhar; Schick, Andreas Journal: Addictive behaviors Issue: Volume 86(2018) Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗